Tilray Shares Show Signs of Technical Rebound

Following a turbulent start to December, Tilray Brands is exhibiting signs of a technical recovery. This recent price surge comes in the wake of a completed reverse stock split and significant volatility earlier in the week. The critical question for investors is whether the share price can now stabilize above the $8.00 mark.

Beyond the immediate technical factors, Tilray continues to pursue its strategic diversification, including expansion in alcoholic beverages and international medical cannabis operations. However, the short-term price action is currently dominated by the market's recalibration following the reverse stock split.

The trading environment for Tilray is characterized by pronounced volatility. From a chartist's perspective, the $8.00 level plays a pivotal role. A sustained position above this threshold would suggest the ongoing recovery has further to run. Conversely, a breakdown below this support zone would indicate the recent gains may merely be a temporary rally within a broader downward trend.

Post-Split Volatility and Trading Dynamics

The share price closed at $8.26 on Wednesday, marking a gain of approximately 2.1%. This followed a substantial 12.36% advance to $8.09 on Tuesday, distancing the stock significantly from its lows seen at the beginning of the week.

This heightened volatility is primarily attributed to the recent adjustment in the company's capital structure:
* Reverse Stock Split: Executed on December 2nd, the 1-for-10 reverse split consolidated shares.
* Reduced Float: The number of outstanding shares decreased from roughly 1.16 billion to approximately 116 million.
* Market Impact: The resulting smaller free float amplifies price movements, as evidenced by Tuesday's double-digit percentage jump.

Should investors sell immediately? Or is it worth buying Tilray?

In the near term, technical factors are prevailing as the market digests the new price level and a reduced supply of tradable shares.

Analyst Perspective and Valuation Adjustments

Despite the recent upward move, market experts remain cautious, largely viewing the equity as a turnaround speculation with limited, though present, upside potential.

The investment bank TD Cowen recently revised its assessment:
* Price Target: Lowered from $25.00 to $10.00.
* Rating: Maintained a "Buy" recommendation.
* Valuation Methodology: Applied an EV/EBITDA multiple of 12x to an anticipated EBITDA figure of $80 million.
* Upside Potential: Based on the $8.26 closing price, this implies a theoretical upside of around 21%.

This adjustment signals reduced optimism compared to TD Cowen's previous stance, yet the firm continues to identify valuation reserves relative to the current trading level.